SI2056807T1 - Zdravljenje vnetnih bolezni - Google Patents

Zdravljenje vnetnih bolezni

Info

Publication number
SI2056807T1
SI2056807T1 SI200731077T SI200731077T SI2056807T1 SI 2056807 T1 SI2056807 T1 SI 2056807T1 SI 200731077 T SI200731077 T SI 200731077T SI 200731077 T SI200731077 T SI 200731077T SI 2056807 T1 SI2056807 T1 SI 2056807T1
Authority
SI
Slovenia
Prior art keywords
treatment
inflammatory diseases
inflammatory
diseases
Prior art date
Application number
SI200731077T
Other languages
English (en)
Inventor
Betty C. Soliven
Original Assignee
University Of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Chicago filed Critical University Of Chicago
Publication of SI2056807T1 publication Critical patent/SI2056807T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200731077T 2006-08-17 2007-08-17 Zdravljenje vnetnih bolezni SI2056807T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83822206P 2006-08-17 2006-08-17
EP07837041A EP2056807B1 (en) 2006-08-17 2007-08-17 Treatment of inflammatory diseases
PCT/US2007/018331 WO2008021532A2 (en) 2006-08-17 2007-08-17 Treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
SI2056807T1 true SI2056807T1 (sl) 2012-12-31

Family

ID=38941849

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731077T SI2056807T1 (sl) 2006-08-17 2007-08-17 Zdravljenje vnetnih bolezni

Country Status (17)

Country Link
US (3) US8258150B2 (sl)
EP (2) EP2392320A1 (sl)
JP (3) JP5216769B2 (sl)
CN (2) CN101553216B (sl)
AU (1) AU2007284337B2 (sl)
BR (1) BRPI0715950A2 (sl)
CA (1) CA2660880C (sl)
DK (1) DK2056807T3 (sl)
ES (1) ES2393631T3 (sl)
HK (1) HK1131047A1 (sl)
HR (1) HRP20121034T1 (sl)
MX (1) MX2009001788A (sl)
PL (1) PL2056807T3 (sl)
PT (1) PT2056807E (sl)
RU (1) RU2440110C2 (sl)
SI (1) SI2056807T1 (sl)
WO (1) WO2008021532A2 (sl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2414205T3 (es) 2006-06-02 2013-07-18 The Ohio State University Research Foundation Agentes terapéuticos para el tratamiento de linfoma de células del manto
PT2056807E (pt) 2006-08-17 2012-12-21 Univ Chicago Tratamento de doenças inflamatórias
CA2730751A1 (en) * 2008-07-23 2010-01-28 Novartis Ag Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
KR20110049870A (ko) * 2008-08-18 2011-05-12 노파르티스 아게 탈수초성 말초 신경병증의 치료를 위한 아미노 알콜 유도체
JP5624037B2 (ja) * 2008-08-18 2014-11-12 ノバルティスアーゲー 末梢神経障害の治療のための化合物
EP2177521A1 (en) 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
CA2739901A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators
CA2740484C (en) 2008-10-17 2021-09-21 Akaal Pharma Pty Ltd S1p receptors modulators and their use thereof
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
US8461362B2 (en) 2009-04-13 2013-06-11 The Ohio State University Research Foundation Protein phosphatase 2A-activating agents
WO2010121111A1 (en) 2009-04-17 2010-10-21 The Ohio State University Research Foundation Antiadhesion agents
JP5859438B2 (ja) 2009-08-10 2016-02-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドを用いたｂｄｎｆ関連疾患の治療
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
ES2558556T3 (es) * 2010-03-03 2016-02-05 Teva Pharmaceutical Industries Ltd. Tratamiento de nefritis lúpica usando laquinimod
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
US8309768B2 (en) 2010-11-29 2012-11-13 The Ohio State University Research Foundation FTY720-derived anticancer agents
EP2766020A4 (en) 2011-10-12 2015-04-01 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
KR20140138694A (ko) 2012-02-03 2014-12-04 테바 파마슈티컬 인더스트리즈 리미티드 최선의 항-TNFα 요법에 실패한 크론병 환자를 치료하기 위한 라퀴니모드의 용도
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
EP2708898A1 (de) * 2012-09-14 2014-03-19 Sterna Biologicals GmbH & Co. Kg Verfahren zur Diagnose eines molekularen Phänotyps eines an einer mit chronischen Entzündungen einhergehenden Erkrankung leidenden Patienten
MX2015005632A (es) 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
BR112015021602A2 (pt) 2013-03-14 2017-07-18 Teva Pharma cristais de laquinimod de sódio e processo melhorado para a fabricação dos mesmos
CN103992985A (zh) * 2014-05-09 2014-08-20 上海大学 神经鞘氨醇在中枢神经系统中的作用
CN112237575A (zh) * 2020-11-09 2021-01-19 杭州端丽生物技术有限公司 芬戈莫德在防治鞘脂紊乱引起的神经退行性疾病中的医药用途
CN112924432A (zh) * 2021-04-08 2021-06-08 济宁市第一人民医院 一种血液真菌感染检测试剂盒及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948820A (en) * 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
WO2000076982A1 (en) * 1999-06-16 2000-12-21 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
TWI376363B (en) 2002-09-24 2012-11-11 Novartis Ag Pharmaceutical combination for treating demyelinating disease
JP4861177B2 (ja) * 2003-09-12 2012-01-25 ニューロノバ エービー 神経系の障害の処置
PT2056807E (pt) * 2006-08-17 2012-12-21 Univ Chicago Tratamento de doenças inflamatórias

Also Published As

Publication number Publication date
JP2015221824A (ja) 2015-12-10
JP2010500995A (ja) 2010-01-14
CA2660880A1 (en) 2008-02-21
EP2392320A1 (en) 2011-12-07
HRP20121034T1 (hr) 2013-01-31
WO2008021532A2 (en) 2008-02-21
US9101576B2 (en) 2015-08-11
EP2056807B1 (en) 2012-09-26
US9370497B2 (en) 2016-06-21
US20100310547A1 (en) 2010-12-09
JP2013144694A (ja) 2013-07-25
RU2009109418A (ru) 2010-09-27
JP5216769B2 (ja) 2013-06-19
CN101553216A (zh) 2009-10-07
AU2007284337A1 (en) 2008-02-21
ES2393631T3 (es) 2012-12-26
CN101553216B (zh) 2012-03-21
RU2440110C2 (ru) 2012-01-20
CA2660880C (en) 2015-10-13
PL2056807T3 (pl) 2013-02-28
US8258150B2 (en) 2012-09-04
US20130017190A1 (en) 2013-01-17
AU2007284337B2 (en) 2012-07-19
BRPI0715950A2 (pt) 2013-07-30
WO2008021532A3 (en) 2008-05-29
CN102526736A (zh) 2012-07-04
PT2056807E (pt) 2012-12-21
US20150335666A1 (en) 2015-11-26
CN102526736B (zh) 2016-01-20
EP2056807A2 (en) 2009-05-13
DK2056807T3 (da) 2012-10-22
MX2009001788A (es) 2009-09-23
HK1131047A1 (en) 2010-01-15

Similar Documents

Publication Publication Date Title
HK1131047A1 (en) Treatment of inflammatory diseases
IL186749A0 (en) Dihydrothienopyrimidines for the treatment of inflammatory diseases
IL200368A0 (en) Treatment of diseases characterized by inflammation
ZA200710598B (en) Treatment of inflammatory conditions
EP2182983A4 (en) TREATMENT OF AMYLOIDOGENIC DISEASES
PT2044111E (pt) Abordagem seletiva do fator h do complemento para o tratamento de doenças
EP2068864A4 (en) THERAPEUTIC USES OF UROLITHINS
HK1138850A1 (en) Quinoline derivatives for the treatment of inflammatory diseases
EP2004204A4 (en) TREATMENT OF NEURODEGENERATIVE DISEASES
PT2056863T (pt) Tratamento de doenças oculares
GB0700972D0 (en) Treatment of inflammatory disease
IL200091A (en) Kittensan to treat infectious diseases of the nail
GB0610183D0 (en) Treatment of neurodegenerative diseases
ZA200905364B (en) Treatment of diseases characterized by inflammation
PL2012814T3 (pl) Sposoby leczenia chorób autoimmunologicznych
GB0720976D0 (en) Treatment of inflammatory disease
EP1981343A4 (en) TREATMENT OF INFLAMMATORY DISEASES WITH TRIAZOL COMPOUNDS
GB0526394D0 (en) Treatment of inflammatory diseases
GB0622136D0 (en) Treatment of gastrointestinal diseases
GB0623740D0 (en) Treatment of disease
GB0622137D0 (en) Treatment of gastrointestinal diseases
ZA200904660B (en) Treatment of IL-1-Beta related diseases
IL194261A0 (en) S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
GB0411302D0 (en) Treatment of inflammatory diseases
GB0609789D0 (en) Treatment of inflammation